Author:
Straesser Matthew D.,Oliver Eric,Palacios Thamiris,Kyin Timothy,Patrie James,Borish Larry,Saini Sarbjit S.,Lawrence Monica G.
Reference10 articles.
1. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria;Maurer;N Engl J Med,2013
2. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria;Kaplan;J Allergy Clin Immunol,2016
3. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature;Tonacci;Pharmacotherapy,2017
4. Zheng Y, Kha L, Wada R, Jin J, Putnam W, Rosén K. Population PK-PD and exposure-response modeling and simulation to support dose recommendations of Xolair in chronic idiopathic urticaria/chronic spontaneous urticaria. Poster presented at American Association of Pharmaceutical Scientists National Biotechnology Conference, May 19-21, 2014, San Diego, Calif (presentation not publicly available).
5. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis;Metz;J Dermatol Sci,2014
Cited by
92 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献